Clinical applications of TNF-alpha in cancer (Q77485569)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Clinical applications of TNF-alpha in cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

F J Lejeune

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

C Rüegg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

D Liénard

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

Current Opinion in Immunology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

573-580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

Tumor necrosis factor (TNF).

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

First experience and technical aspects of isolated liver perfusion for extensive liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

High serum levels of TNF-α after its administration for isolation perfusion of the limb

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Thrombocytopenia and complement activation under recombinant TNF alpha/IFN gamma therapy in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980226-4

7 January 2021

10.1016/S0952-7915(98)80226-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794839%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference